Madrigal Pharmaceuticals, Inc. Annual Reports (10-K)
Every annual report 10-K going back 38 years. Put here in one place for you.
Page 1 of 38
2026-2010
| Currency in USD | 2026 |
|---|---|
| Operating Income | -56.31 Million |
| Income Before Tax | -57.94 Million |
| Income Tax Expense | N/A |
| Net Income | -57.94 Million |
| Eps | -1.99 |
| Epsdiluted | -1.99 |
| Weighted Average Shs Out | 29.15 Million |
| Weighted Average Shs Out Dil | 29.15 Million |
| Research And Development Expenses | N/A |
| Selling General And Administrative Expenses | 289.38 Million |
| Depreciation And Amortization | 381.00 Thousand |
| Interest Expense | 7.94 Million |
| Interest Income | 7.10 Million |
| Net Interest Income | -836 Thousand |
| Premiums Earned | N/A |
| Policyholder Benefits | N/A |
| Gross Profit | 324.25 Million |
| Ebitda | -55.93 Million |
| Source | edgar |
| Ebit | -50 Million |